Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODADS: Optimal Initial Dose of Antivenom for Russell's Viper Envenoming
NCT04210141Phase 2Suspended
- Sponsor
- Myanmar Oxford Clinical Research Unit
- Start
- Apr 2025
- Primary completion
- Feb 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of BPI viper antivenom in Daboia siamensis envenoming, sponsored by Myanmar Oxford Clinical Research Unit. Started Apr 2025; status: suspended.
02
Drugs
BPI viper antivenom
03
Conditions
Daboia siamensis envenoming
Beyond the preview
Go deeper on NCT04210141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04210141.